<DOC>
	<DOCNO>NCT00087334</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop tumor cell divide stop grow die . Gefitinib may stop growth tumor cell block enzymes necessary growth . Combining capecitabine oxaliplatin gefitinib may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose capecitabine give together oxaliplatin gefitinib see well work treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin , Gefitinib Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose capecitabine give combination oxaliplatin gefitinib patient metastatic colorectal cancer . ( phase I ) - Determine response rate patient treat regimen . ( phase II ) Secondary - Determine safety toxic effect regimen patient . - Determine 1-year survival patient treat regimen . ( phase II ) - Determine progression-free overall survival patient treat regimen . ( phase II ) OUTLINE : This open-label , nonrandomized , phase I , dose-escalation study capecitabine follow phase II study . - Phase I : Patients receive oral capecitabine twice daily day 1-14 oxaliplatin IV 2 hour day 1 . Patients also receive oral gefitinib daily begin 5 day initiation capecitabine oxaliplatin continue duration study treatment . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive oral capecitabine ( MTD determine phase I ) , oxaliplatin IV , oral gefitinib phase I . Patients follow survival . PROJECTED ACCRUAL : A total 3-24 patient accrued phase I portion study within 1-12 month ; total 26 patient accrue phase II portion study within 8-13 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirmed* colorectal cancer Metastatic disease The site primary tumor must confirm endoscopically , radiologically , surgically colon rectum NOTE : *Confirmation require recurrent metastatic disease unless interval &gt; 5 year elapse initial primary surgery development metastases Measurable disease At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No CNS metastases PATIENT CHARACTERISTICS : Age 18 80 Performance status ECOG 01 Life expectancy More 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion allow ) Hepatic AST ALT ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ ULN No unstable uncompensated hepatic disease Renal Creatinine &lt; 1.5 time ULN OR Creatinine clearance &gt; 60 mL/min No unstable uncompensated renal disease Cardiovascular No unstable uncompensated cardiac disease Pulmonary No evidence clinically active interstitial lung disease Asymptomatic patient chronic stable radiographic change eligible No unstable uncompensated respiratory disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No known hypersensitivity gefitinib excipients No known hypersensitivity platinum compound , fluorouracil , capecitabine No severe uncontrolled systemic disease Able receive oral medication No known dihydropyrimidine dehydrogenase ( DPD ) deficiency No known peripheral neuropathy ≥ grade 1 Absence deep tendon reflex sole neurological abnormality allow No significant clinical disorder laboratory find would preclude study participation No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix ( phase II ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 4 week since prior chemotherapy metastatic colorectal cancer ( phase I ) No prior chemotherapy metastatic disease ( phase II ) Prior fluorouracil leucovorin calcium adjuvant setting allow provide last treatment administer 6 month development metastatic disease No prior irinotecan oxaliplatin ( phase II ) Endocrine therapy Not specify Radiotherapy No concurrent radiotherapy colorectal cancer Surgery See Disease Characteristics More 4 week since prior major surgery ( e.g. , laparotomy ) Other Recovered prior therapy ( unresolved chronic toxicity &gt; grade 2 ) More 4 week since prior investigational drug No prior epidermal growth factor receptor inhibitor therapy ( phase II ) No concurrent phenytoin , carbamazepine , rifampin , barbiturate , Hypericum perforatum ( St. John 's wort ) No concurrent investigational drug No concurrent systemic therapy colorectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>